MIHOPE-Strong Start, a collaboration of the Centers for Medicare and Medicaid Services, the Administration for Children and Families, and the Health Resources and Services Administration, assesses the impacts of home visiting programs for disadvantaged expectant mothers. This report describes the study and the programs: Healthy Families America and Nurse-Family Partnership.
The Continuing Story of the Opportunity NYC−Family Rewards Demonstration
Family Rewards, a three-year demonstration, provided cash payments to low-income families in New York City for achieving specific health, education, and employment goals. New results show that the program substantially reduced poverty and material hardship while it operated and had positive results in improving some education, health, and work-related outcomes.
Home visiting programs seek to improve maternal and child outcomes by supporting families with young children. The Affordable Care Act of 2010 included $1.5 billion for the Maternal, Infant, and Early Childhood Home Visiting (MIECHV) program, with a national evaluation required. This report describes the design of that evaluation.
While we know how to help low-income individuals prepare for and find work, too many end up in low-wage jobs and never advance up the career ladder. This policy memo describes what we’ve learned about advancement strategies — both those that show promise and those that don’t work.
A Research Note for Funders
Targeted toward very low-income families in six high-poverty New York City communities, Family Rewards offers cash payments tied to efforts and achievements in children’s education, family preventive health care practices, and parents’ employment. This paper reviews data on participants’ receipt of rewards and offers preliminary estimates of the program’s impacts on selected educational outcomes during the first year.
This report presents a preliminary analysis of the cost of operating Britain’s Employment Retention and Advancement (ERA) demonstration, which is being evaluated though a large-scale randomised control trial. This assessment of costs will become an important element of the full cost-benefit analysis to be presented in future ERA reports.